Drug Trial Radar · NCT06682780
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Sep 17, 2025
Primary completion
Dec 25, 2028
Study completion Dec 1, 2029
Sponsor
- Lead sponsor
- LaNova Medicines LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.
Conditions
- Advanced Solid Tumor
Interventions
LM-2417Drug
Q2W/Q3W,Intravenous Drip
DocetaxelDrug
Q3W,Intravenous Drip
Toripalimab/TirelizumabDrug
Q3W,Intravenous Drip
CarboplatinDrug
Q3W,Intravenous Drip
NiraparibDrug
QD,Oral Administration
LenvatinibDrug
QD,Oral Administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: 60 weeks
- Incidence of dose-limitingtoxicity (DLT)Time frame: 60 weeks
- Incidence of serious adverse event (SAE)Time frame: 60 weeks
- TemperaturesTime frame: 60 weeks
- Pulse in BPM(Beat per Minute)Time frame: 60 weeks
- Blood Pressure in mmHgTime frame: 60 weeks
- Weight in KgTime frame: 60 weeks
- Height in centimeterTime frame: 60 weeks
- Laboratory tests-Blood Routine examinationTime frame: 60 weeks
- Laboratory tests-Urine Routine testTime frame: 60 weeks
- Laboratory tests-Blood biochemistryTime frame: 60 weeks
- Laboratory tests- Coangulation functionTime frame: 60 weeks
- Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 60 weeks
- 12-lead electrocardiogram (ECG) in HRTime frame: 60 weeks
- 12-lead electrocardiogram (ECG) in RRTime frame: 60 weeks
- 12-lead electrocardiogram (ECG) in PRTime frame: 60 weeks
- 12-lead electrocardiogram (ECG) in QRSTime frame: 60 weeks
- 12-lead electrocardiogram (ECG) in QTTime frame: 60 weeks
- 12-lead electrocardiogram (ECG) in QTcFTime frame: 60 weeks
- ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 60 weeks
- Overall Response Rate (ORR)Time frame: 76 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
FuDan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.